Lee Schwartzberg, MD, FACP

Lee Schwartzberg, MD, discusses important questions that have been raised due to the positive results of pembrolizumab immunotherapy for patients with triple-negative breast cancer.

Lee Schwartzberg, MD, discusses the concerns of treating patients with early triple-negative breast cancer with immunotherapy.

Lee Schwartzberg, MD, discusses the results of the KEYNOTE-522 trial of pembrolizumab in patients with early triple-negative breast cancer.

The proper management of chemotherapy-induced toxicities can have a significant impact on quality-of-life and outcomes for patients.

During a Targeted Oncology Case-Based Peer Perspectives virtual event, Lee Schwartzberg, MD, medical oncologist, West Cancer Center and Research Institute, discussed the therapeutic options for a 39-year-old woman with HER2-positive breast cancer who was heavily pretreated.

The goal of selecting optimal antiemetic therapy continues to be a moving target with the emergence of newer agents and patient-related risk factors, as well as the rapid evolution of guidelines for the management of chemotherapy-induced nausea and vomiting.